Clinical Proteomics Becomes Reality: Protein Profiling Enters Routine Liver Disease Testing in Denmark
For many years, LC-MS based proteomics has shown potential to become one of the most promising technologies in diagnostic science. Being able to measure large numbers of proteins directly in patient samples offers a new level of insight into disease biology – with the potential to support earlier detection, improved stratification, and better monitoring of treatment response.
But one key question has always been:
When will proteomics move beyond research and become part of everyday clinical care?
In Denmark, that transition is no longer theoretical – it has already begun.
Clinical proteomics is now making its way into routine healthcare, where general practitioners in Region Sjælland and Region Hovedstaden can order a protein-profile-based risk assessment of liver disease through the Danish public system. It is an important milestone for LC–MS-based diagnostics, and a clear signal that proteomics is entering a new phase.
From Research Workflows to Clinical Diagnostics
Introducing proteomics into the clinic is not a simple matter.
Clinical laboratories work under very different conditions than academic research environments. Methods must be standardized, results must be reproducible, and workflows must run reliably day after day across hundreds and even thousand of samples.
For proteomics to succeed in patient care, LC-MS platforms need to deliver:
- Consistent performance
- Quantitative robustness
- Scalability for large patient cohorts
- Seamless fit within existing hospital infrastructure
This has been one of the major barriers to adoption. Until recently, most proteomics workflows were simply not designed with clinical implementation in mind.
Liver Risk Assessment Through Routine Ordering in Denmark
At the Department of Clinical Biochemistry at Bispebjerg and Frederiksberg Hospital, clinical proteomics has now reached a new stage of maturity.
The department has established a high-throughput LC–MS platform and implemented a protein-based liver disease risk profile that can be ordered directly through an electronic healthcare system.
That point is significant: this type of testing is not only being explored in clinical studies, but is becoming accessible through the same infrastructure used for routine diagnostics in everyday patient care.
Enabling Clinical-Scale Proteomics With Evosep Eno
Turning proteomics into something that works at the clinical scale requires more than analytical depth. It requires operational stability, throughput, and confidence in day-to-day performance.
By coupling the Evosep Eno with high-resolution mass spectrometry, the clinical biochemistry team has established a workflow that supports sensitive and reproducible protein measurements at a pace aligned with clinical demand. The Chief Physician elaborates that:
“By implementing LC–MS-based plasma proteomics in a clinical setting, we are demonstrating that protein profiling can move beyond pilot studies and into real-world diagnostics. What we are building in Denmark has clear relevance for healthcare systems globally.”
Nicolai J. Wewer Albrechtsen, Chief Physician at Department of Clinical Biochemistry, Copenhagen University Hospital – Bispebjerg and Clinical Professor at Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen
Why Throughput and Standardization Matter
Proteomics holds enormous clinical potential, but that potential depends on whether results can be delivered reliably and consistently also at scale.
High-throughput LC-MS proteomics can support:
- Validation of clinically relevant biomakers
- More precise diagnostics stratification
- Monitoring of disease progression and treatment response
- Faster translation from discovery to clinical assays
In a clinical context, standardization is not optional. We see it as a foundation for trust, reproducibility, and long-term implementation.
Denmark as a Front Runner in Clinical Proteomics
The availability of a proteomics-based liver disease risk assessment within Denmark’s public healthcare system is a powerful example of what is slowly now becoming possible. It shows that protein profiling by LC–MS has matured to the point where it can support real diagnostic decision-making – not as an experimental technology, but as part of implemented clinical practice. For Denmark, it represents important progress in precision diagnostics. For the wider community, it offers a glimpse of what the future may look like.
